Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SCIO Scios Inc. -- Ignore unavailable to you. Want to Upgrade?

To: ubrx who wrote (956)	12/30/1998 2:30:00 AM
From: JimmyD	Read Replies (2) \| Respond to of 1477

Jim and all, What's the relationship (if any) between Fibroblast and Fiblast? This is from a small article on page 61 of the January issue of Discover magazine: "In February a team led by a researcher at the Fulda Clinic in Germany reported that they'd coaxed new blood vessels to grow in the hearts of patients with blocked coronary arteries. The study is the first clinical trial of an experimental technique that involves injecting a genetically engineered protein -- fibroblast growth factor -- into tissue surrounding blocked coronary arteries. Within three months, all 20 treated patients had grown new blood vessels."

To: ubrx who wrote (956)	12/30/1998 2:49:00 AM
From: Miljenko Zuanic	Respond to of 1477

Jim: Note on FIBLAST PI/II for stroke and in collaboration with NIH for CAD was first time mentioned in October 23, 1996, announcement about agreement and collaboration with AHP. Honestly, I am not holding my breath for any news regards the data from this trials. SCIO didn't release any data from stroke PII trial, so why will they do now for CAD/PVD? AHP restriction, I guess! :( Nonetheless, I will not be surprised if they (after CHIR started their PII trial with almost the same protein) start large PII or even pivotal PII/III trial for CAD in near future. Miljenko